Belite Bio, Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BLTE Nasdaq 2836 www.belitebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Belite Bio, Inc

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results - Aug 6th, 2026 6:00 am
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - Jul 22nd, 2026 3:02 pm
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - Jul 20th, 2026 6:00 am
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - Jul 15th, 2026 6:00 am
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease - Jul 9th, 2026 9:02 pm
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - Jul 6th, 2026 6:00 am
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - Jul 6th, 2026 5:00 am
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - Jun 12th, 2026 7:30 pm
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn - Jun 12th, 2026 12:45 pm
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 2nd, 2026 6:00 am
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - May 20th, 2026 11:00 pm
Belite Bio Q1 Earnings Call Highlights - May 20th, 2026 4:06 pm
Belite Bio (BLTE) Q1 2026 Earnings Transcript - May 20th, 2026 3:59 pm
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - May 20th, 2026 4:57 am
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - May 20th, 2026 4:00 am
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland - May 18th, 2026 2:00 pm
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) - May 15th, 2026 6:00 am
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results - May 13th, 2026 2:00 pm
Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission - May 3rd, 2026 12:08 am
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - May 1st, 2026 4:10 am